S10 Ep44: Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

OncLive® On Air - Un podcast de OncLive® On Air

Essayez Nextory gratuitement pendant un mois.

Un univers rempli de livres audio, cliquez ici pour essayer

Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.